Novartis results for CANOPY|1 study support further evaluation of ...

Novartis top-line results for CANOPY-1 Phase III study support ...

The CANTOS trial evaluated canakinumab as a secondary prevention measure for cardiovascular events in patients following a heart attack3,11.

canopy-1 - Cancer Trial Results

P3, N=245; CANOPY-2 (NCT03626545); Sponsor: Novartis Pharmaceuticals; "Novartis announced today the Phase III CANOPY-2 study evaluating canakinumab (ACZ885)...

Repositioning canakinumab for non-small cell lung cancer ... - NCBI

1. Novartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancer | Novartis n.d. https ...

Novartis top-line results for CANOPY-1 Phase III study support ...

The trial data, however, showed potentially clinically meaningful improvements in both PFS and OS in pre-specified subgroups of patients based ...

Novartis provides update on Phase III CANOPY-A study evaluating ...

“While we are disappointed CANOPY-A did not show the benefit we hoped for, every trial generates scientific evidence that supports future ...

Canakinumab as Adjuvant Therapy in Patients With Completely ...

CANOPY-A did not show a DFS benefit of adding canakinumab after surgery and adjuvant cisplatin-based chemotherapy in patients with resected, stage II-III NSCLC.

Novartis results for CANOPY-1 study support further evaluation of ...

“CANOPY-1 provides critical insights into the treatment of this devastating disease, and we will continue to analyze the data and conclusions, ...

LBA49 CANOPY-A - Annals of Oncology

Legal entity responsible for the study: Novartis Pharmaceuticals Corporation. ... Conclusions: These findings further support neoadjuvant N + C vs C as a novel.

Novartis provides update on Phase III study evaluating ...

Basel, March 9, 2021 — Novartis announced today the Phase III CANOPY-2 study evaluating canakinumab (ACZ885), an inhibitor of interleukin-1beta ...

Novartis Shows Growing Strength in Lung Cancer Innovation with ...

CANOPY-A is a Phase III multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of canakinumab as ...

Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in ...

GlobeNewswire 2022 - Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer open_in_new.

Novartis announces Tabrecta® first published overall survival and ...

Now we have further evidence that Tabrecta, the market-leading treatment specifically for METex14 NSCLC patients4, has the potential to help people live longer, ...

Novartis announces analysis published in The Lancet showing ...

Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies ...

Capmatinib in MET exon 14-mutated non-small-cell lung cancer

Herein, we report the final activity and safety results from the GEOMETRY mono-1 study in treatment-naive and in previously treated patients ...

Novartis highlights new findings in advancing care for patients with ...

Additional pipeline research in melanoma, breast cancer and solid tumors at ASCO. Initial results from a Phase I study of LGX818 in patients with BRAF V600 ...

Sponsor Specific Details: Novartis - ClinicalStudyDataRequest.com

For future Novartis studies patients will be asked to give permission for broader research beyond the original study intent so other research may be possible ...

Results of a randomized double-blind placebo-controlled Phase 2 ...

Thus, our findings support further evaluation of iptacopan in the ... Publication types. Randomized Controlled Trial; Clinical Trial, Phase II ...

CANOPY phase III program: Three studies evaluating canakinumab ...

Trial design ; Treatment scheme · 18 cycles of treatment, 4 cycles of induction (canakinumab or placebo + CTx + pembrolizumab) followed by maintenance ( ...

Model Patient Information and Informed Consent - ClinicalTrials.gov

to study side effects that might result from taking palbociclib with standard endocrine therapy, and to help researchers learn about how the study treatment ...

LBA4 CANOPY-N: A phase II study of canakinumab (CAN) or ...

CANOPY-N did not meet the primary endpoint of MPR rate, with minimal clinical efficacy and no increase in CD8+ T cells with CAN alone. No new safety signals ...